The company's hardware platform, MT-100, automates the production and injection of the gold standard tracer 15O-water into the patient, while their analytical software platform interprets the results from the PET scanner. By using 15O-water, doctors can increase sensitivity in patient analysis and increase patient throughput up to four times compared to current clinical methods. MedTrace's devices automate bedside production and infusion of radioactive water in the PET scanner suite, transforming blood flow quantification and enabling physicians to focus on heart-study applications, brain and tumour vascularization, and diabetes studies. With strong investors such as ATP, BankInvest, Swisscanto Private Equity, Vækstfonden, and the European Innovation Council, MedTrace Pharma A/S is rapidly growing with offices in Denmark and the US.